Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by James L. Bown
Kinetic Modelling of in Vitro Data of PI3K, mTOR1, PTEN Enzymes and On-Target Inhibitors Rapamycin, BEZ235, and LY294002
European Journal of Pharmaceutical Sciences
Pharmaceutical Science
Related publications
BEZ235 Impairs Gastric Cancer Growth by Inhibition of PI3K/mTOR in Vitro and in Vivo
BMC Pharmacology
Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease
Clinical Journal of the American Society of Nephrology
Epidemiology
Nephrology
Critical Care
Transplantation
Intensive Care Medicine
Mechanistic Target of Rapamycin Inhibitors: Successes and Challenges as Cancer Therapeutics
Retraction: Mammalian Target of Rapamycin Inhibitors for Treatment in Tuberous Sclerosis
Korean Journal of Pediatrics
Child Health
Pediatrics
Perinatology
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
Frontiers in Oncology
Cancer Research
Oncology
Synergistic Effects of Phenylhexyl Isothiocyanate and LY294002 on the PI3K/Akt Signaling Pathway in HL‑60 Cells
Oncology Letters
Cancer Research
Oncology
NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro
Acta Pharmacologica Sinica
Medicine
Pharmacology
Glycolytic Glioma Cells With Active Glycogen Synthase Are Sensitive to PTEN and Inhibitors of PI3K and Gluconeogenesis
Laboratory Investigation
Forensic Medicine
Pathology
Cell Biology
Molecular Biology
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
Cancer Research
Cancer Research
Oncology
